Fusion Pharmaceuticals Inc. FUSN
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 1.83B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -12.68
- Beta
- -0.69
- Short ratio
- 6.22
- Inst. own
- 86.80%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 7, 2024
- 50-d avg
- 21.40
- 200-d avg
- 10.83
- 1y target
- 21.14
Key statistics
- Market cap
- 1.83B
- Enterprise value
- 1.69B
- Trailing P/E
- 0.00
- Forward P/E
- -12.68
- PEG ratio
- 0.00
- Price / sales
- 898.55
- Price / book
- 7.56
- EPS (TTM)
- -1.40
- Beta
- -0.69
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 2.04M
- Revenue growth
- 0.00%
- Free cash flow
- -57.11M
- Total cash
- 210.52M
- Total debt
- 64.55M
- Return on equity
- -47.11%
- Shares outstanding
- 85.06M
- Short % of float
- 4.22%
- 50-day average
- 21.40
- 200-day average
- 10.83
Analyst view
Consensus: hold
- Target (low)
- 20.00
- Target (mean)
- 21.14
- Target (high)
- 23.00
Next earnings
May 7, 2024
Expected May 7, 2024. Consensus EPS estimate -0.34.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 7, 2024 | Mar 1, 2024 | -0.38 | — | — | — |
| Mar 20, 2024 | Dec 1, 2023 | -0.34 | — | — | — |
| Nov 7, 2023 | Sep 1, 2023 | -0.40 | — | — | — |
| Aug 8, 2023 | Jun 1, 2023 | -0.39 | — | — | — |
| May 11, 2023 | Mar 1, 2023 | -0.29 | — | — | — |
| Mar 16, 2023 | Dec 1, 2022 | -0.57 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 2023 | B. Riley Securities | reit | Buy | Buy |
| Sep 28, 2023 | Oppenheimer | init | — | Outperform |
| Aug 27, 2023 | Raymond James | main | Outperform | Outperform |
| Jun 27, 2023 | Wedbush | reit | Outperform | Outperform |
| Jun 22, 2023 | Raymond James | init | — | Outperform |
| Mar 29, 2023 | B. Riley Securities | reit | — | Buy |
About Fusion Pharmaceuticals Inc.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada. As of June 4, 2024, Fusion Pharmaceuticals Inc. operates as a subsidiary of AstraZeneca AB.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- fusionpharma.com
News
- Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2023
- Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2022
- Why Vintage Wine Estates Shares Tumbled 40%; Here Are 70 Biggest Movers From Yesterday
- Stocks That Hit 52-Week Lows On Thursday
- Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2022
- Stocks That Hit 52-Week Lows On Thursday
- Stocks That Hit 52-Week Lows On Wednesday
- Stocks That Hit 52-Week Lows On Monday
- Stocks That Hit 52-Week Lows On Thursday
Your note
Sign in to keep a note on FUSN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS STREET PARTNERS L L C | Beneficial Owner of more than 10% of a Class of Security | Sale | Dec 23, 2020 | 0 |
| CROWLEY JOHN JOSEPH CPA | Chief Financial Officer | Stock Award(Grant) | Aug 30, 2021 | 10,410 |
| GANNON STEVEN R | Director | Purchase | Aug 10, 2022 | 56,400 |
| JOHNSON & JOHNSON | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 29, 2020 | 0 |
| KHUONG CHAU QUANG | Director | Stock Award(Grant) | Nov 10, 2022 | 42,093 |
| LEAMON CHRISTOPHER P | Officer | Stock Award(Grant) | Aug 30, 2023 | 11,957 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes, Inc. | 15.41% | 10,633,789 | 49.66M | Jun 29, 2023 |
| Avidity Partners Management, LP | 8.26% | 5,700,000 | 26.62M | Jun 29, 2023 |
| FMR, LLC | 6.78% | 4,681,457 | 21.86M | Jun 29, 2023 |
| Johnson & Johnson | 5.32% | 3,670,516 | 17.14M | Jun 29, 2023 |
| Orbimed Advisors LLC. | 4.53% | 3,122,770 | 14.58M | Jun 29, 2023 |
| Canada Pension Plan Investment Board | 4.52% | 3,116,966 | 14.56M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Kaufmann Small Cap Fund | 3.64% | 2,510,000 | 8.16M | Jul 30, 2023 |
| Fidelity Advisor Biotechnology Fund | 2.24% | 1,546,014 | 5.02M | Jul 30, 2023 |
| Fidelity Select Portfolios - Biotechnology | 1.20% | 830,309 | 2.47M | Aug 30, 2023 |
| Federated Hermes Kaufmann Fund | 0.72% | 500,000 | 1.63M | Jul 30, 2023 |
| Federated Hermes International Small/Mid Company Fund | 0.22% | 150,000 | 390.00K | Sep 29, 2023 |
| Federated Hermes Kaufmann Fund II | 0.17% | 118,789 | 554.74K | Jun 29, 2023 |